# A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)

> **NCT06456567** · PHASE3 · WITHDRAWN · sponsor: **Vor Biopharma**

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** Telitacicept
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06456567
- **Lead sponsor:** Vor Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-09
- **Primary completion:** 2025-01-02
- **Final completion:** 2025-01-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor business decision
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06456567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06456567, "A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06456567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*